MET and neoplasm: Moreover, Kumai et al. [82] showed that MET expression itself behaves as a tumor-associated antigen and that it is able to activate CD4+ T-cells and to induce tumor cell killing in NK/T-cell lymphoma (NKTCL) cell lines.